FSD Pharma Announces Collaboration with iNGENu CRO for Lucid-MS Clinical Study

FSD Pharma Inc., a leading biopharmaceutical company, announced a new partnership with iNGENu CRO Pty Ltd to conduct a phase 1 clinical study on Lucid-21-302 (Lucid-MS), aimed at evaluating its safety and pharmacokinetics in healthy adult participants. The agreement, signed through its subsidiary HUGE Biopharma Australia Pty Ltd, marks a significant step in FSD Pharma's mission to develop innovative treatments for multiple sclerosis (MS).

Lucid-21-302 is a pioneering neuroprotective compound designed for the treatment of MS. It operates through a unique mechanism that prevents demyelination in the central nervous system, which is crucial in battling MS and other neurodegenerative diseases. Previous studies showed Lucid-21-302 to be safe and well-tolerated, laying a strong foundation for the upcoming clinical trial.

Dr. Andrzej Chruscinski, Vice-President of Scientific and Clinical Affairs at FSD Pharma, emphasized the company's commitment to efficiently completing the clinical trial. With promising data from initial studies, FSD Pharma and iNGENu are set to embark on this fruitful collaboration, hoping to bring novel therapeutics to the forefront of MS treatment.